



IBA – ACQUISITION OF OWN SHARES COMPLETION OF THE SHARE BUYBACK PROGRAM

Immediate Release – March 10th, 2022

Louvain-la-Neuve, Belgium, March 10th, 2022 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on December 3rd, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 400.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until June 30th, 2022, effective as from December 6th, 2021, to cover the remaining portion of the company’s obligation of shares delivery as part of a long-term incentive plan granted to certain employees in 2021 in the form of stock options.

In the framework of this share buyback program, IBA repurchased 15.595 IBA shares on Euronext Brussels in the period from March 7th, 2022, up to and including March 8th, 2022, as follows:

Trade date	Shares purchased	Average price	Min price	Max price	Buyback amount
07-03-22	10.000	16,64 €	16,88 €	16,26 €	166.422,00 €
08-03-22	5.595	17,00 €	17,30 €	16,70 €	95.106,05 €
TOTAL	15.595	16,77 €	16,88 €	16,70 €	261.528,05 €

The total number of shares purchased under this program therefore amounts to 400.000 which terminates the program, at an average price of 16,4532 EUR/share. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SCRL) is the following:

	Shares	Voting rights
IBA Investments SCRL	51.973	51.973
IBA SA	1.077.935	1.140.212
Total - Treasury shares	1.129.908	1.192.185
Total - Issued shares	30.218.718	38.339.545
Treasury shares in %	3,74%	3,11%

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs

Press Release

Regulated information



approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

Contact person

IBA

Christian Matton,

IBA Chief Legal Officer

shareholderrelations@iba-group.com